| Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (NCT03755739) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer (NCT03111901) | William Grosh, MD | 2018-10-29 |
| Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (NCT03354962) | Institut Claudius Regaud | 2018-10-15 |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors (NCT03685591) | Pfizer | 2018-10-04 |
| A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (NCT03711188) | Immodulon Therapeutics Ltd | 2018-10-04 |
| Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors (NCT03946007) | University Medical Center Groningen | 2018-10-04 |
| Pembrolizumab and EDP1503 in Advanced Melanoma (NCT03595683) | University of Chicago | 2018-10-02 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors (NCT03665285) | NextCure, Inc. | 2018-10-01 |
| Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (NCT03747744) | Universitair Ziekenhuis Brussel | 2018-09-28 |
| Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma (NCT03683550) | University Hospital, Essen | 2018-09-25 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma (NCT03635983) | Bristol-Myers Squibb | 2018-09-21 |
| Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (NCT03620019) | UNC Lineberger Comprehensive Cancer Center | 2018-09-10 |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (NCT03484923) | Novartis Pharmaceuticals | 2018-09-10 |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (NCT03455764) | Dana-Farber Cancer Institute | 2018-09-10 |
| NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (NCT03399448) | University of Pennsylvania | 2018-09-05 |
| TNF in Melanoma Patients Treated With Immunotherapy (NCT03348891) | Institut Claudius Regaud | 2018-09-05 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (NCT03611868) | Ascentage Pharma Group Inc. | 2018-08-29 |
| Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma (NCT03941756) | M.D. Anderson Cancer Center | 2018-08-14 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (NCT03552718) | NantBioScience, Inc. | 2018-08-10 |
| POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors (NCT04193956) | University Medical Center Groningen | 2018-08-01 |
| A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US (NCT03732560) | Bristol-Myers Squibb | 2018-07-31 |
| Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma (NCT03528408) | Suthee Rapisuwon | 2018-07-26 |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma (NCT03336606) | Providence Health & Services | 2018-07-25 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma (NCT03580382) | NYU Langone Health | 2018-07-06 |
| Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (NCT03412058) | UNICANCER | 2018-06-27 |
| Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (NCT03501368) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-27 |
| CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) (NCT03504488) | BioAtla, Inc. | 2018-06-27 |
| Skin Self-Examination Education During Mammography (NCT03512457) | Northwestern University | 2018-05-30 |
| Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer (NCT03480152) | National Cancer Institute (NCI) | 2018-05-18 |
| Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (NCT03224208) | Fondazione Melanoma Onlus | 2018-05-17 |
| Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients (NCT04680182) | Oslo University Hospital | 2018-05-11 |
| Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma (NCT03476174) | Ralph Hauke | 2018-05-07 |
| A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (NCT03565406) | NYU Langone Health | 2018-04-25 |
| Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer (NCT03300843) | National Cancer Institute (NCI) | 2018-04-11 |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (NCT03470922) | Bristol-Myers Squibb | 2018-04-11 |
| Preventing Lymphedema in Axillary Lymph Node Dissection (NCT03428581) | Mayo Clinic | 2018-04-10 |
| Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 (NCT03313544) | Assistance Publique Hopitaux De Marseille | 2018-04-09 |
| Investigating the Clinical Utility of the MDS (NCT03109327) | Orlucent, Inc | 2018-04-01 |
| Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations (NCT03454919) | Peking University Cancer Hospital & Institute | 2018-03-30 |
| Fecal Microbiota Transplant (FMT) in Melanoma Patients (NCT03341143) | Zarour, Hassane, MD | 2018-03-19 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (NCT03435640) | Nektar Therapeutics | 2018-03-15 |
| CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (NCT03511391) | University Hospital, Ghent | 2018-03-09 |
| SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients (NCT03126461) | University of Texas Southwestern Medical Center | 2018-03-01 |
| 18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy (NCT03741231) | University Hospital, Brest | 2018-03-01 |
| Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma (NCT02719015) | M.D. Anderson Cancer Center | 2018-03-01 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Melanoma Accuracy Study; Phase 2 (NCT03464604) | Nova Scotia Health Authority | 2018-02-28 |
| A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers (NCT03400332) | Bristol-Myers Squibb | 2018-02-12 |
| Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients (NCT03374839) | Nantes University Hospital | 2018-02-12 |
| Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases (NCT02974803) | Canadian Cancer Trials Group | 2018-02-09 |
| Preclinical Validation of New Anti-melanoma Compounds (NCT03798977) | Centre Hospitalier Universitaire de Nice | 2018-02-01 |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors (NCT03454035) | UNC Lineberger Comprehensive Cancer Center | 2018-01-30 |
| Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy (NCT03407040) | National Cancer Institute (NCI) | 2018-01-30 |
| Dabrafenib and/or Trametinib Rollover Study (NCT03340506) | Novartis Pharmaceuticals | 2018-01-26 |
| Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (NCT03754179) | Universitair Ziekenhuis Brussel | 2018-01-23 |
| A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma (NCT03391050) | Aprea Therapeutics | 2018-01-18 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma (NCT03328247) | University of Aberdeen | 2018-01-12 |
| Treating Patients With Melanoma and ALK Alterations With Ensartinib (NCT03420508) | Memorial Sloan Kettering Cancer Center | 2018-01-10 |
| The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany (NCT03205722) | Bristol-Myers Squibb | 2018-01-05 |
| Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (NCT03259425) | University of Utah | 2018-01-03 |
| Polish Microbiome Map (NCT04169867) | Ardigen | 2018-01-01 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Optimization of the Patient Care Pathway in Immuno-oncology (NCT03329755) | Institut Claudius Regaud | 2017-12-26 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962) | Genentech, Inc. | 2017-12-21 |
| Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) (NCT03241927) | Nina Bhardwaj | 2017-12-20 |
| Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma (NCT02917473) | University Hospital, Tours | 2017-12-13 |
| A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NCT03301636) | NewLink Genetics Corporation | 2017-12-08 |
| Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (NCT03161756) | Melanoma and Skin Cancer Trials Limited | 2017-12-07 |
| Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions (NCT03362138) | Assuta Hospital Systems | 2017-12-06 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (NCT03167177) | ImmunityBio, Inc. | 2017-12-01 |
| An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma (NCT03329846) | Bristol-Myers Squibb | 2017-11-30 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
| How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes (NCT03370861) | Washington University School of Medicine | 2017-11-08 |
| Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma (NCT03352947) | Cambridge University Hospitals NHS Foundation Trust | 2017-11-03 |
| Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma (NCT03356470) | University of Wisconsin, Madison | 2017-11-02 |
| A Study of BCD-135 in Patients With Advanced Solid Tumors (NCT03464032) | Biocad | 2017-10-31 |
| The Impact of Melanoma and Drug Treatment in the Real World (NCT03379454) | Vitaccess Ltd | 2017-10-25 |
| TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (NCT03293784) | Institut Claudius Regaud | 2017-10-16 |
| Tracing Dissemination of Melanoma Cells in Healthy Tissues (NCT02854124) | Assistance Publique - Hôpitaux de Paris | 2017-10-12 |
| Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy (NCT03267381) | Vanderbilt-Ingram Cancer Center | 2017-10-03 |
| Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma (NCT03472027) | Biocad | 2017-10-02 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| REO13 Melanoma With of Without GM-CSF (NCT03282188) | University of Leeds | 2017-10-01 |
| SunSmart Intervention in Schools (NCT03745872) | University of Colorado, Denver | 2017-09-26 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (NCT03171064) | University Hospital Heidelberg | 2017-09-05 |
| Study of HL-085 in NRAS Mutant Advanced Melanoma (NCT03973151) | Shanghai Kechow Pharma, Inc. | 2017-09-01 |
| International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma (NCT03269565) | Biocad | 2017-08-31 |
| EPR Tumor Oximetry With CE India Ink (NCT03321903) | Philip Schaner | 2017-08-30 |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NCT03207867) | Novartis Pharmaceuticals | 2017-08-28 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174) | Sarcoma Oncology Research Center, LLC | 2017-08-24 |
| Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection (NCT02910557) | Amgen | 2017-08-10 |
| Liquid Biopsy Evaluation and Repository Development at Princess Margaret (NCT03702309) | University Health Network, Toronto | 2017-08-03 |
| A Sunscreen Based on Bioadhesive Nanoparticles (NCT02668536) | Yale University | 2017-07-17 |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab (NCT03123783) | Apexigen America, Inc. | 2017-07-10 |